Neuberger Berman Group LLC Has $2.04 Million Position in Illumina, Inc. $ILMN

Key Points

• Neuberger Berman Group LLC reduced its holdings in Illumina, Inc. by 82.5% in the first quarter, bringing its total shares to 25,749, valued at approximately $2.04 million.
• Several hedge funds have made recent moves regarding Illumina, with notable increases in holdings from firms like PFS Partners LLC (400% increase) and Rakuten Securities Inc. (290.3% increase).
• Illumina reported an EPS of $1.19 for the last quarter, exceeding analysts' expectations, but the company's revenue of $1.06 billion fell short of estimates, marking a 4.8% decline year-over-year.

Neuberger Berman Group LLC reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 82.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,749 shares of the life sciences company's stock after selling 121,445 shares during the quarter. Neuberger Berman Group LLC's holdings in Illumina were worth $2,043,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the company. Capital World Investors raised its stake in Illumina by 408.6% during the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after purchasing an additional 14,481,232 shares during the period. Vanguard Group Inc. raised its stake in shares of Illumina by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock valued at $1,298,928,000 after acquiring an additional 558,243 shares during the period. WCM Investment Management LLC raised its stake in shares of Illumina by 1.2% in the 1st quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company's stock valued at $334,321,000 after acquiring an additional 49,156 shares during the period. Brown Advisory Inc. raised its stake in shares of Illumina by 52.1% in the 1st quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company's stock valued at $230,818,000 after acquiring an additional 996,589 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Illumina by 26.9% in the 4th quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company's stock valued at $220,882,000 after acquiring an additional 349,878 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Up 0.8%

Shares of Illumina stock traded up $0.7950 on Tuesday, hitting $101.3250. The company had a trading volume of 523,362 shares, compared to its average volume of 2,349,190. The stock has a 50-day moving average of $97.12 and a 200-day moving average of $89.34. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The firm has a market capitalization of $15.57 billion, a P/E ratio of 12.82, a P/E/G ratio of 2.25 and a beta of 1.37. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm's revenue for the quarter was down 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

ILMN has been the subject of several recent analyst reports. Scotiabank lowered shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price objective for the company. in a report on Friday, July 11th. Robert W. Baird boosted their price target on shares of Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a research report on Monday, July 28th. Royal Bank Of Canada boosted their target price on shares of Illumina from $118.00 to $126.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Canaccord Genuity Group lifted their target price on shares of Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a research report on Friday, August 1st. Finally, Daiwa Capital Markets downgraded shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective on the stock. in a research report on Tuesday, August 12th. Seven investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $124.58.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.